FDA sees asthma drug risks

By Lisa Richwine

WASHINGTON (Reuters) - U.S. regulators remain concerned about serious risks from a class of asthma drugs and will ask U.S. advisers next week if approval for treating the lung disease should be revoked, documents released on Friday said.

Staff in the Food and Drug Administration’s drug-safety office unanimously recommended withdrawing the approval of all long-acting beta agonist drugs, or LABAs, for children under age 18 amid evidence of an increased risk of asthma-related deaths and asthma attacks.

LABAs include GlaxoSmithKline Plc’s Advair and Serevent, AstraZeneca Plc’s Symbicort and Novartis AG’s Foradil, which Schering-Plow Corp markets in the United States.

The drug-safety staff, which monitors risks of drugs after approval, also urged removing the approval of Serevent and Foradil for asthma in people of all ages.

Serevent and Foradil contain LABAs only, while Advair and Symbicort combine LABAs with an inhaled steroid.

Adding the steroid may protect against serious complications, as Glaxo has argued. An FDA “meta-analysis” of several studies found the risk “was not apparent” in Advair or when a LABA was used with a steroid, agency documents said.

A memo outlining the advisory panel meeting said the agency would ask the outside experts if the drugs should still be approved for treating asthma. The panel meets Wednesday and Thursday.

Dr. Badrul Chowdhury, director of the FDA division that reviews pulmonary and allergy drugs, noted a “serious and significant safety risk” but added the asthma-related deaths were “numerically small” and the benefits were “not trivial.”

“Removal of inhaled LABAs from the market as a treatment for asthma is a way of managing the risk of these drugs, but would be an extreme approach that could be problematic,” Chowdhury wrote.

The drugs also are approved for treating chronic obstructive pulmonary disease and would remain available for treating that lung disease.

The makers of the drugs, in separate documents prepared for the meeting, said the benefits outweighed their risks when used as directed.

(Additional reporting by Susan Heavey, editing by Dave Zimmerman)


Related Posts:

By Susan Heavey WASHINGTON (Reuters) - Data show Novartis AG’s combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday. “The majority of AEs (adverse events) were of mild or moderate intensity. Deaths … and SAEs (serious adverse events) … were

Full Post: Novartis malaria drug safe, effective: FDA

LONDON (Reuters) - Pills used to treat common skin infections caused by fungi also appear to help some people with severe asthma, according to a British study published on Monday. Volunteers with an allergic reaction to one or more fungi showed significant improvements in their asthma after taking antifungal itraconazole pills, David Denning at University Hospital

Full Post: Antifungal pills could help treat asthma: study

By Megan Rauscher NEW YORK (Reuters Health) - In children with both asthma and gastroesophageal reflux disease (GERD), treating the latter can improve the former, according to research presented Sunday at the annual meeting of the American College of Allergy, Asthma and Immunology in Seattle. GERD is a common disease in which fluid from the stomach backs

Full Post: Treating reflux helps kids with asthma

By Susan Heavey WASHINGTON (Reuters) - Alpharma Inc’s powerful painkiller Embeda, which contains morphine sulfate and Duramorph, may not thwart drug abusers despite design features aimed at discouraging its misuse, U.S. regulatory staff said in documents released on Wednesday. The drugmaker tested the effects of the design features only when the pill was misused orally, but addicts

Full Post: FDA staff cite abuse concern with Embeda

NEW YORK (Reuters) - New data do not signal any heart risks with Takeda Pharmaceutical Co Ltd’s experimental drug to treat acid build-up in patients with gout, a top U.S. Food and Drug Administration official said in a document released on Thursday. Takeda is seeking U.S. approval to sell its drug febuxostat for chronic gout patients

Full Post: No heart risk seen with Takeda gout drug: FDA

Site Navigation

Most Read



  • kinwrite.com@gmail.com